Schering-sponsored Seldane study shows declines in co-administration of contraindicated drugs.
Executive Summary
SELDANE OVERLAPPING USE WITH CONTRAINDICATED DRUGS DECLINED FROM 5.4% TO 2.3% between January 1990 and June 1994, Brookline, Mass.-based Policy Analysis researchers David Thompson, PhD, and Gerry Oster, PhD, report in a study published in the May 1 issue of the Journal of American Medical Association. The retrospective study was funded by Hoechst Marion Roussel competitor Schering-Plough, which markets the antihistamine Claritin.